PsiloThera, Inc.

Psychedelic Healthcare Innovation

PsiloThera, Inc.

Psychedelic Healthcare Innovation

Henderson, NV
Biotechnology
Psilothera is a pioneering mental health care company dedicated to creative, modern solutions to treat global healthcare concerns, including depression, anxiety, PTSD, eating disorders, addictions, Alzheimer’s, dementia, and more. We plan to deploy quantum technology to shorten the drug development time, which will give us an advantage over our competitors. With a focus on healing, hope, and compassion, we aim to change the paradigm of mental healthcare with their Psilocybin-based therapies.

$135,846

raised
127
Investors
$50M
Valuation
$5.00
Price per Share
$500.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$5M
Offering Max
Reg CF
Offering

$135,846

raised
127
Investors
$50M
Valuation
$5.00
Price per Share
$500.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$5M
Offering Max
Reg CF
Offering

Rewards

Get rewarded for investing more into PsiloThera, Inc.:

$500+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$50,000+
Investment
Tier 1: $50,000+
Invest $50,000 or more and receive 5% bonus shares
$75,000+
Investment
Tier 2: $75,000+
Invest $75,000 or more and receive 7% bonus shares
$100,000+
Investment
Tier 3: $100,000+
Invest $100,000 or more and receive 10% bonus shares

Reasons to Invest

Psilothera is stepping into the scene of major healthcare crisis by focusing on medical research breakthroughs and groundbreaking legalizations
The company is actively targeting a $100 billion market opportunity in Psilocybin healthcare
Psilothera is led by a battle tested management team with business model, strategy and plan driven by research and development

The Problem


The world is in the throes of a mental health crisis   


Recent estimates from the World Health Organization show that roughly 322 Million People suffer from Major Depression Disorder. In the US alone, 16 million people suffer from this debilitating disease. What’s worse is that up to a third of the people suffering from clinical depression are “treatment resistant,” meaning traditional antidepressants don’t treat them. This resistance is one of the reasons why 17.6 veterans commit suicide a day in the United States. With the current state of the mental healthcare industry, they have no other options for medication.



A recent Gallup poll shows that the pharmaceutical industry is the least trusted industry in America. Toxic industry norms, widespread corruption, as well as harsh side effects of mental health medicine have created a need for a viable alternative among patients and consumers. (Source





THE SOLUTION


Psilocybin-based therapy is revolutionizing the world of mental healthcare


Psilothera commits to providing new remedies for mental wellness by creating compounds for Psilocybin-based treatments. Psilocybin assisted therapy gives the patient the opportunity to fully engage in self-reflection and personal expression, ultimately shift emotional and behavior patterns.  




The technique used in Psilocybin assisted therapy is microdosing. Microdosing is the regular intake of very small quantities of psychedelic substances. Microdosing is beneficial because while there are minimal acute effects reported, these substances claim a range of long-term health and well-being benefits. We believe the fear of having a “bad trip” on Psilocybin makes microdosing a more approachable option for the millions of people suffering. 



THE MARKET


Vertical integration powered by quantum technology



Psilothera’s battle tested leadership team is made up of entrepreneurs, mental health professionals, and mushroom farmers. This team agrees on the same mission: be one of the first companies focused on developing Psilocybin-based therapeutics while deploying quantum technology. We are currently in the final stages of procuring a technology licensing agreement with a well-known quantum technology company, which will drastically reduce the development time as well as the cost of therapeutics. 






OUR TRACTION


Gaining momentum by the day


Breakthrough studies by reputable programs such as Journal of JAMA Psychiatry, Johns Hopkins Center for Psychedelic & Consciousness Research, Imperial College, and US National Library of Medicine National Institute of Health have all shown promising results on psychedelics’ ability to treat long-lasting depressive, PTSD, and anxiety symptoms with minimal side effects. 


Psilothera’s partnership with the Zoom Healthcare ISV Program to develop its tele-health mental health care video platform is paving the way for groundbreaking development in online Psilocybin-based treatment. 




Psilothera is pre-revenue and our Fungi Grow & Lab is in its pre-launch stage. Once launched, the lab will begin researching, growing, and developing 20 different types of Psilocybe Cubensis, providing us with a robust portfolio of therapeutic fungi. 


The varieties of mushrooms to be used in our formulations include Reishi, Lion’s Mane, Turkey Tail, Shiitake, Maitake, and Oyster. Reishi, for example, is being studied and used for its anticancer potential at the Memorial Sloan Kettering Cancer Center. Our Mushroom Nutraceutical product line for cancer patients is designed to support their current treatments program.



On a global scale, in November 2020, Oregon became the first state in the United States to legalize Psilocybin, allowing supervised use of psilocybin in a therapeutic setting.


Furthermore, voters around the country have decriminalized in Washington DC, Denver, Oakland, Ann Arbor, Houston, Somerset and Cambridge, MA so far. Psilothera projects widespread movement towards Legalization and Decriminalization by 2023.






WHY INVEST


The time to invest is now


A major paradigm shift is occurring in the healthcare sector. Breakthrough medical studies, a string of groundbreaking legalizations, and an unprecedented public openness to psychedelics has paved the road for Psilocybin-based therapy to be a legitimate alternative to pharmaceutical products. Psilothera aims to deploy this cutting edge medicine to establish itself as a beacon of hope, wellness, and compassion in the mental health market.


gif


Annual sales for antidepressants, ADHD, anxiety, and anti-addiction medications well exceed $30 billion, and an increasing number of studies are showing a potential for Psilocybin and other psychedelic-based therapies to be as or even more effective than their pharmaceutical counterparts, meaning potential billions in revenue. 


Our mushrooms aren't magic. They're therapeutic, backed by science. We believe they're the future of mental health treatment.





THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.




Offering Summary


Company

:

PsiloThera, Inc.

Corporate Address

:

17 Cerchio Basso, Henderson, NV 89011

Offering Minimum

:

$10,000.00

Offering Maximum

:

$5,000,000.00

Minimum Investment Amount

(per investor)

:

$500.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

2,000

Maximum Number of Shares Offered

:

1,000,000

Price per Share

:

$5.00

Pre-Money Valuation

:

$50,000,000.00











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below. Note these perks do stack with the other offering perks. You will only receive the highest level bonus share perk you are eligible for.

Company Perks*

Time-Based Perks

Friends & Family Bonus

Invest in the first 72 hours and receive 10% bonus shares.

Amount-Based Perks

Tier 1: $50,000+

Invest $50,000 or more and receive 5% bonus shares

Tier 2: $75,000+

Invest $75,000 or more and receive 7% bonus shares

Tier 3: $100,000+

Invest $100,000 or more and receive 10% bonus shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Psilothera will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $5.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $500. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$0.00 USD
$0.00 USD
Cash And Cash Equivalents
$0.00 USD
$0.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$0.00 USD
$0.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
$0.00 USD
$0.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Psilothera CEO John Atanasio to Speak at The Cannabis Investment Summit.- Feb 2nd

2 days ago

Hi Psilothera Investors

Psilothera CEO John Atanasio to Speak  at The Cannabis Investment Summit.- Feb 2nd.   Happy to  be invited and this gives Psilothera  another platform to share our story.

John Atanasio, CEO


Notice of Funds Disbursement

3 days ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.

3 days ago

Hi Startengine Investors,

Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.

This is a great platform to share our story.

We have over 400 investors watching on the Startengine.

We have outstanding momentum and please invest now.

John Atanasio, CEO


Psilothera's CEO John Atanasio on Stage at Wonderland Miami 2021-Video

10 days ago

Hi StartEngine  Investors

Psilothera's  CEO John Atanasio on Stage at Wonderland Miami 2021 Video

https://youtu.be/P3BUv9HRRIw


Notice of Funds Disbursement

18 days ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Psilothera video CEO Presents at PsyCap Psychedelic Investor Conference

24 days ago

Hi Startengine Investors,

I was recently a presenter at the PsyCap  an Online Psychedelic Investor Conference  that took place.Last week and below is some video.

https://youtu.be/J837H93gBGE


PSILOTHERA- Quantum Technology Comments and Article

25 days ago

Hi Startengine Investors

A few of you asked about Quantum Technology. Below is a link to a article that also discusses Drug Discovery. We believe that  being an early leader  using Quantum Technology and AI in our labs is critical.
I believe Quantum  Technology may be game changing next level technology and worth pursuing.

https://www.zdnet.com/article/quantum-computers-eight-ways-quantum-computing-is-going-to-change-the-world/

John Atanasio, CEO

Seattle Votes to Decriminalize Psilocybin

29 days ago

Hi  Startengine Investors,

Seattle Votes to Decriminalize Psilocybin.

This is huge as the City Council has indicated that are following the lead of Oregon. 

Psilothera shall apply for Licensing on Oregon and other markets as they become available.  Oregon shall commence  its licensing application process in January 2023.

Psilothera to Sponsor Wonderland- Miami

about 1 month ago

Psilothera  is proud to announce that we will be a major sponsor of  Wonderland- Miami, the 1st and largest major Psychedelic Conference of its kind.  The Genie is out of the bottle ... the World will know about Psilothera.

Psilothera- Psychedelic Capital Conference Presentation & Free Ticket

about 1 month ago

If you missed the Psychedelic Capital  event you can still view the entire event online.

Just go to link and type JOHNA or Psilothera for free ticket

Psilothera “Lets Talk Story” 1st Investor Virtual Conference Video

about 1 month ago

Psilothera “Lets Talk Story” 1st Investor Virtual Conference.

John Atanasio CEO and Charles Atanasio, Director of Research   chat about Psilothera, Psilocybin Therapy, Vet Suicide Prevention  and their Mission to heal and save lives.

https://vimeo.com/635780632

pw: WOLF

Psilothera -Free Ticket to Psychedelic Capital Conference 10/28

about 1 month ago

Hi Startengine Investors,

Ill be presenting tomorrow 10/28 at the Psychedelic Capital Conference. Check out the link on graphic and use Code: JOHNA for free ticket. I’ll be discussing our Treatment Focus, Vertical Business Model and our Vet and 1st Reponder Programs.


Toronto’s University Health Network launches psychedelic psychotherapy research centre

about 1 month ago

Hi Startengine Investors.

Some important industry news.

Toronto’s University Health Network launches psychedelic psychotherapy research centre | The Province" here: https://share.smartnews.com/izmsw

Boris Johnson to consider calls to legalise magic mushroom drug psilocybin"

about 1 month ago

"Boris Johnson to consider calls to legalise magic mushroom drug psilocybin" here: https://share.smartnews.com/UQuNB

Psilothera announces plan to launch Clinic in San Antonio, Texas- Military City, USA

about 1 month ago

Psilothera  is proud to announce our plans to open a Psilothera Clinic in San Antonio, Texas- Military City, USA.

Psilothera Mental Health Treatment Programs shall serve Vets, 1st Responders and suffering Patients.

NIH Grants Johns Hopkins $4 Million for Psychedelic Mushrooms

about 2 months ago

The National Institutes of Health (NIH) gave the Johns Hopkins health system nearly $4 million in grant money to study the effects of psychedelic mushrooms, according to a Monday announcement.

Notice of Funds Disbursement

about 2 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Psilothera Industry News- Seattle Decriminalized Psilocybin-Invest Now!

about 2 months ago

Hi Starte Engine Investors,

Great News on the regulatory front!

Seattle Decriminalized Psilocybin.

I encourage all investors that are on the sidelines to jump in now!

John Atanasio, CEO & Founder

Psilothera Leadership Spotlight- Michelle Pon Tell Head Therapist-Advisor LCSW, MA, CCTP,Founder

2 months ago

Michelle Pon Tell

Head Therapist-Advisor LCSW, MA, CCTP,Founder  

Michelle is a Certified Clinical Trauma Professional, clinically trained in Somatic Experiencing, a method ideally suited to gently releasing the stress, anxiety, trauma and overwhelm trapped in one's body. This powerful modality allows clients to quickly resolve past emotional issues so they can move forward with a sense of joy and freedom.

Her experiences working with Hospice, as well as providing intensive in-home therapy to families, has allowed Michelle the humbling privilege of walking with all types of individuals through some of life's most difficult circumstances. Whatever your situation, she is available to meet you where you are and help you get to where you want to be.

PsiloThera Leadership Spotlight-Jan Rydfords, Doctor- Medical Advisor, Founder

2 months ago

Jan Rydfords, Doctor- Medical Advisor, Founder

Dr. Rydfors received his Medical degree and specialization training from Stanford University Medical Center where he is an Adjunct Clinical Professor. 

He is the Chief Medical Advisor for the American Pregnancy Association and acts as a Medical Advisor for several Silicon Valley Companies. He is the recipient of the Compassionate Doctor, Marquis who’s who in the world and Patient’s Choice award.

Dr Rydfors has extensive experience in high risk Obstetrics, advanced fertility treatment and treatment of recurrent miscarriages. Over the last 30 years, Dr Rydfors has developed a successful multidisciplinary program to prevent recurrent miscarriages which attracts patients from all over the US. His interests include also autism prevention in pregnancy. 

He is the initial creator and current Co-Author of the popular “Handbook in Obstetrics, Gynecology and Infertility,” now in its sixth edition, the main handbook used by all Obstetricians and Gynecologists in training in the US. He was the founder of OBOnTheGo and EmbraceHerHealth which made the most complete medical grade pregnancy Mobile Apps when they came out and currently is a co-founder of EverDoc where powerful AI and Machine Learning is being used to optimize medical care.

 

PsiloThera Leadership Spotlight-Jacquelyn Wright-Minogue- Advisor- Clinical Trials-Founder

2 months ago

Jacquelyn Wright-Minogue Advisor- Clinical Trials & Founder

Jacquelyn Wright-Minogue, MS, PMP has over 30 years of pharmaceutical industry experience. Jackie first joined Schering-Plough in the pathology area. She then moved onto basic research and clinical research in several therapeutic areas such as pathology, virology, allergy and immunology, oncology and rare diseases. 

Her cloning, RT-PCR and DNA sequencing knowledge and skills led her to an adjust professor teaching position at a Kean University where she taught master level courses in DNA sequencing. Feeling the need to get closer to the patient experience after 20 years in basic scientific research, Jackie leaves Schering-Plough/Merck, and moves onto Novartis to work on oncology trials. 

Working on clinical trials for medulloblastoma in children and basal cell carcinoma. The drug was approved by the FDA as sonidegib for locally advanced basal cell carcinoma. From big pharma, Jackie moved onto a small biotech company called Amicus Therapeutics where she quickly advanced to her current role as Sr. Director of Clinical Operations.Jackie helped spearhead and enrolled the largest ever trial in Pompe Disease in record time, keeping patients on study during a global pandemic. 

It is her life mission to get medication to those in need. During the pandemic more people are suffering from mental illness than ever before. Jackie believes that this unmet medical need could benefit from a healthier, natural option with less side effects than traditional medicine.

PsiloThera Leadership Spotlight- "Chaplain Chuck" Atanasio, Director of Research

2 months ago

"Chaplain Chuck" Atanasio

Director of Research, Psychologist, Retired Army Major, Chaplain & Behavioral Specialist- Bronze Star Recipient

Chaplain Chuck has  developed the Psilothera  proprietary therapeutic approach and shall oversee  our Veteran  & 1st Responder Therapy & Suicide Intervention/Prevention Programs.

Chaplain Chuck's notable  career and experience in  treating or training the Military, brings unique qualifications and understanding to help PsiloThera lead a  Veteran & 1st Responder based  psilocybin mental health treatment program. It is important to note, that a psilocybin therapist assisted  patient  treatment experience has been expertly described as where  "Science and  Spirituality Meet."

Chaplain Chuck has served for 25+ years in a leadership and 1st Responder role and capacity to provide Mental Health & Spirituality Care to Military Personal & their Families. 

Chaplain Chuck trained hundreds of military personnel once a year in suicide prevention for 16 years. He has also been Certified to Train First Responders on suicide intervention. An Iraqi Combat Vet, he has served 25 years in the military as an Army Chaplain and as a Behavioral Science Specialist. 

Chuck has a MSW Degree in Social Work from Marywood University and a MS in Experimental Psychology from Purdue University and a BA in Psychology from Seton Hall University. 

Notable Service of Achievement and Invaluable Experience:

Awarded:  Bronze Star GWOT Expeditionary Medal for Military Service, 2003-2004. GWOT=Global War on Terrorism. Operation Iraqi Freedom; Awarded General Petraeus Excellence in Combat Coin. 

Awarded Key to City, Keysport, Tennessee for Adopt-A-Platoon work and leadership: During Operation Iraqi Freedom, 2003-2004, Chaplain Chuck spearheaded the Adopt-A-Platoon initiative which coordinated and distributed numerous care packages from American non-profits and citizens to approximately 5,000 Soldiers in Iraq.

Chaplain Chuck has provided compassionate spiritual needs assessments, care & counseling to increase the resiliency of hundreds of individuals, couples and families in: burn wards, combat operations, in-patient psychiatric wards critical incidents, emergency rooms, funeral homes, hospice, hospitals, memorials, military deployments and exercises, nursing homes, orphanages, prisons, relationship enhancement retreats and work office settings.

Psilothera Comment:

"Chaplain Chuck is my one and only Brother. IMO, No one better to  lead a program  to help save and heal our  Vets and 1st Responders where spiritual and scientific approaches to achieve better  patient outcomes  can be explored."

John Atanasio, CEO & Founder

PsiloThera Files U.S. Trademarks

3 months ago

Hi Start Engine Investor Community,

Like any Industry your brand and brand  message is important.

We filed  U.S. Trademarks Applications for the following Trademarks:

Company Name: PsiloThera

Company Tagline: Psychedelic Healthcare Innovation

PsiloThera Product Tagline: "Our Mushrooms Aren't Magical, They're Therapeutic."

Thanks for your support!  

John Atanasio, CEO & Founder


PsiloThera Announces the Launch of its Pre-Clinical Quantum Drug & Nutraceutical Development Program -Phase 1

3 months ago

Hi Start Engine Investors,

We are proud to announce the Launch of our Pre-Clinical Quantum Drug & Nutraceutical Development Program -Phase 1

Below is an outline of of what we shall accomplish in Phase 1.

Strategic Planning &  Project Management-Launch-Phase 1. (60-90 days).

  • High-Level Open-Architecture Overview 
  • Quantum Chemistry Laboratory Design Proposal
  • Extraction Strategy and Customized Quantum Production Proposals
  • Quantum Material Sciences Supply Chain Documents
  • Remediation Strategy Proposal
  • Distributed Sales License Agreement
  • Written and Agreed Upon Communication Documents
  • Video - Explanation of Quantum and Digaceuticals 

Thank for your interest and consideration.  We would like to invite you all into our Ohana & Family of Investors. 

John Atanasio, CEO & Founder

Psilothera Files U.S. Patents

3 months ago

PsiloThera, Inc. a Leader in Psychedelic Healthcare Innovation Announces the Filing of U. S. Patents Protecting Its Proprietary Psychedelic Assisted Therapeutic  Process, Tele-Mental Health & Microdosing Platform.

 

Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

InvestorPlace selects PsiloThera as a "Best Startup to Invest In!"

4 months ago

Psychedelic Healthcare Innovation: PsiloThera Announces Launch of Quantum Technology Drug Development Program.

4 months ago

Psychedelic Healthcare Innovation: PsiloThera Announces Launch of Quantum Technology Drug Development Program.

For Immediate Release: Henderson, Nevada, July 30,2021

PsiloThera, Inc. is a pioneering Psychedelic Healthcare Innovation  & Life Sciences Company developing Psilocybin (“Magic Mushroom”) based Drugs and Therapies proudly announces the launch of its Quantum Technology Drug Development Program.

PsiloThera’s Clinical Focus is the Treatment of Mental Illnesses including: Depression, Anxiety, PTSD, Eating Disorders & Addictions and Cognitive Diseases & Neurological Disorders such as Alzheimer’s, Dementia and Autism. 

PsiloThera’s  specialized teatment programs will provide care for Vets, 1st Responders & Patients with Treatment Resistant Mental Illnesses.

 PsiloThera CEO, John Atanasio states,”PsiloThera  is among the first companies focused on developing novel therapeutics by deploying Quantum Technology  that can collect and send materials through organic devices.“

”PsiloThera’s strategy is to have its products lead the future of energy-based nutrients and medication delivery systems.”  “Quantum technology may lead to advances that could ultimately change the way that Humans digest supplements, medications and nutrients.“

“Our Quantum Technology Advisors projects that the technology projects  to deliver significant improvements in areas  of Pharmaceutical dispensing issues and adverse effects.”

“Quantum Technology may  lead to significant reductions in drug development time and costs, giving PsiloThera a possible major competitive advantage if that were to prove true”

The Journal of American Medical Association- “JAMA PSYCHIATRY” reported in a 2020 study that a treatment of Psilocybin “Magic Mushrooms” works much better than usual anti-depressant medications.

PsiloThera’s outstanding battle tested management team will operate the Company’s  vertical business model  which includes; Fungi Grow, Research & Development, Drug Development, Tele-Mental Health Platform and PsiloThera Treatment Centers.

 

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}